RHEINCELL iPSCs – clinical quality by source and design
Our iPSCs are intended for therapeutic use only. As such we have established cell lines with attributes that maximize their fitness for that purpose.
Clinically collected, donor-consented starting material
Our starting material are CD34+ cells derived from umbilical cord blood that is clinically sourced and accompanied by explicit donor consent to use for therapeutics.
- - Free of the ethical concerns that limit the use of embryonic stem cells
- - Donor-consent to protect the scientific and commercial interests of our customers
- - Controlled collection and extensive testing to ensure pathogen-free lines
Uniquely sourced to ensure genetic integrity
Cord blood cells have intact DNA. Karyotypes of our iPSC lines demonstrate the corresponding chromosome integrity. Accordingly, our iPSCs have a very low mutation load compared to alternative lines.
Indistinguishable from embryonic stem cells
By all measures, our iPSCs are practically identical to human embryonic stem cells (hESC), without the ethical concerns. Morphologically similar, the transcriptional profiles of our iPSCs show near perfect correlation to the profiles of their origin CD34+ cell lines and of hESCs.
Morphologically, our iPSCs are indistinguishable from human embryonic stem cells (hESC). A comparison of the transcriptomic profiles of our iPSCs, their source cord blood cells, and hESC corroborate the equivalency.